Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
2014 · New England Journal of Medicine · 4,520 citations
https://doi.org/10.1056/nejmoa1402584
R
Roland M. du Bois
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
187
Papers
34.9K
Citations
80
h-index
135
i10-index
Roland M. du Bois is an academic researcher from Imperial College London. The author has contributed to research in topics: Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis & Sarcoidosis and Beryllium Toxicity Research & Systemic Sclerosis and Related Diseases. The author has an h-index of 80, co-authored 159 publications.
Papers by this author
worksPirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
2011 · The Lancet · 2,100 citations
https://doi.org/10.1016/s0140-6736(11)60405-4
Idiopathic Nonspecific Interstitial Pneumonia
2008 · American Journal of Respiratory and Critical Care Medicine · 590 citations
https://doi.org/10.1164/rccm.200611-1685oc
Forced Vital Capacity in Patients with Idiopathic Pulmonary Fibrosis: Test Properties and Minimal Clinically Important Difference
2011 · American Journal of Respiratory and Critical Care Medicine · 517 citations
https://doi.org/10.1164/rccm.201105-0840oc
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials
2015 · European Respiratory Journal · 444 citations
https://doi.org/10.1183/13993003.00026-2015
Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis
2016 · Thorax · 176 citations
https://doi.org/10.1136/thoraxjnl-2015-207011
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat